A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2019
Price : $35 *
At a glance
- Drugs Lomitapide (Primary) ; Ethinylestradiol/norgestimate
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Sponsors Aegerion Pharmaceuticals
- 23 Mar 2015 Planned End Date changed from 1 Jun 2014 to 1 Oct 2014, according to to ClinicalTrials.gov record.
- 23 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
- 01 May 2014 Status changed from recruiting to active, no longer recruiting.